Overview

A Study of LY900014 in Healthy Chinese Participants

Status:
Completed
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar. The study will look at how the body processes LY900014 and the affect of LY900014 on blood sugar levels. For each participant, the study will consist of 3 periods and will last about 51 days.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Lispro
Insulin, Globin Zinc